Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial. by Zerah, Lorène et al.
Zerah et al. BMC Geriatr          (2021) 21:571  
https://doi.org/10.1186/s12877-021-02532-z
RESEARCH
Prevalence of drug-drug interactions in older 
people before and after hospital admission: 
analysis from the OPERAM trial
Lorène Zerah1* , Séverine Henrard1,2, Ingeborg Wilting3, Denis O’Mahony4, Nicolas Rodondi5,6, 
Olivia Dalleur1,7, Kieran Dalton8, Wilma Knol9, Manuel Haschke10 and Anne Spinewine1,11 
Abstract (N = 351) 
Background: Drug-drug interactions (DDIs) are highly prevalent in older patients but little is known about preva-
lence of DDIs over time. Our main objective was to assess changes in the prevalence and characteristics of drug-drug 
interactions (DDIs) during a one-year period after hospital admission in older people, and associated risk factors.
Methods: We conducted a sub-study of the European OPERAM trial (OPtimising thERapy to prevent Avoidable 
hospital admissions in Multimorbid older people), which assessed the effects of a structured medication review 
(experimental arm) compared to usual care (control arm) on reducing drug-related hospital readmissions. All OPERAM 
patients (≥70 years, with multimorbidity and polypharmacy, hospitalized in four centers in Bern, Brussels, Cork and 
Utrecht between December 2016 and October 2018, followed over 1 year) who were alive at hospital discharge and 
had full medication data during the index hospitalization (at baseline i.e., enrolment at admission, and at discharge) 
were included. DDIs were assessed using an international consensus list of potentially clinically significant DDIs in 
older people. The point-prevalence of DDIs was evaluated at baseline, discharge, and at 2, 6 and 12 months after 
hospitalization. Logistic regression models were performed to assess independent variables associated with changes 
in DDIs 2 months after baseline.
Results: Of the 1950 patients (median age 79 years) included, 1045 (54%) had at least one potentially clinically 
significant DDI at baseline; point-prevalence rates were 58, 57, 56 and 57% at discharge, and 2, 6 and 12 months, 
respectively. The prevalence increased significantly from baseline to discharge (P < .001 [significant only in the control 
group]), then remained stable over time (P for trend .31). The five most common DDIs –all pharmacodynamic in 
nature– accounted for 80% of all DDIs and involved drugs that affect potassium concentrations, centrally-acting drugs 
and antithrombotics. At 2 months, DDIs had increased in 459 (27%) patients and decreased in 331 (19%). The main 
factor predictive of a change in the prevalence of DDIs was hyperpolypharmacy (≥10 medications).
Conclusions: DDIs were very common; their prevalence increased during hospitalization and tended to remain 
stable thereafter. Medication review may help control this increase and minimize the risk of adverse drug events.
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Background
Drug-drug interactions (DDIs) occur when two or more 
drugs interact on a pharmacokinetic and/or a pharma-
codynamic level, with the risk of increasing the toxicity 
or reducing the intended effect of one or more of the 
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involved drugs [1, 2]. Potential DDIs occur when two 
drugs, known to interact, are prescribed concomitantly; 
actual DDIs can result in adverse drug events (ADEs) or 
treatment failure [3–5].
DDIs are highly prevalent in older people [4, 5] as a 
result of multimorbidity, polypharmacy, age-related 
changes in pharmacokinetics and pharmacodynamics 
that increase the complexity of therapeutic management, 
and treatment by multiple care providers [3, 6–8]. The 
wide variance in DDI prevalence estimates is a conse-
quence of the considerable heterogeneity in definitions 
and methods used to identify DDIs, in study populations 
and in study settings [3–6, 9]. A consensus is needed for 
identification of DDIs in older people in order to facili-
tate comparisons across studies [10]. Recently, an inter-
national European expert consensus panel used a Delphi 
process to develop a list of 66 potentially clinically signifi-
cant DDIs in people aged ≥65 years, which could be used 
to assess the prevalence of DDIs in epidemiological and 
interventional studies [11].
Hospital admission in older people with multimor-
bidity provides an opportunity for medication review, 
including minimizing the inherent risks of DDIs (cur-
rent and over time), which is important because DDIs are 
associated with an increased risk of adverse drug reac-
tions, functional status decline, health services use and 
mortality in older adults [3, 9, 12–15]. DDIs are respon-
sible for approximately 5% of hospital admissions in older 
patients [16–18]. However, prescription of new drugs 
during hospitalization to treat an acute medical problem 
and/or to prevent readmission may increase the risk of 
DDIs, particularly if these DDIs persist at and after dis-
charge. To our knowledge, no study previously assessed 
DDI prevalence over time in older patients, yet such data 
is important to inform medication review strategies.
The European multicenter, cluster randomized, con-
trolled OPERAM (OPtimising thERapy to prevent Avoid-
able hospital admissions in Multimorbid older people) 
trial assessed whether a structured medication review 
reduced drug-related hospital readmissions in older 
patients with multimorbidity and polypharmacy com-
pared with usual care [19]. DDIs 2 months after randomi-
zation, one of the secondary outcomes measured using 
the international consensus list, [11] were highly preva-
lent, with no significant differences between the two 
arms (59.5% of patients in the intervention and 62.2% in 
the control arm) [19]. However, no further evaluation of 
changes in the prevalence of the DDIs was performed in 
this population.
The main objective of the present study was therefore 
to evaluate, in patients included in the OPERAM trial, 
changes in the prevalence of potentially clinically sig-
nificant DDIs during a one-year period after hospital 
admission, using the recently developed list of poten-
tially clinically significant DDIs [11]. Secondary objec-
tives were (i) to identify the most common potentially 
clinically significant DDIs in this population and the drug 
classes involved, (ii) to determine variables associated 
with potentially clinically significant DDIs at trial enrol-
ment, and (iii) to identify factors associated with changes 




The OPERAM trial included older (≥70 years) patients 
with multimorbidity (≥3 chronic medical conditions) 
and polypharmacy (≥5 chronic medications) [19]. In this 
trial, 2008 hospitalized patients were enrolled between 
December 2016 and October 2018 in four medical cent-
ers in Bern (Switzerland), Brussels (Belgium), Cork (Ire-
land) and Utrecht (The Netherlands) [19]. The date of 
study inclusion (baseline,  t0) was the first day of the index 
hospitalization. Follow-up data were collected at the end 
of the index hospitalization (discharge,  t1) and via tele-
phone interviews at 2  (t2), 6  (t6) and 12  (t12) months after 
baseline. A blinded trial team member evaluated and 
reported all medications taken on those dates, as well as 
hospitalizations and deaths. Details of the protocol and 
intervention have been published previously [19–23]. The 
OPERAM trial received approval from ethics committees 
at each site. All methods were performed in accordance 
with the relevant guidelines and regulations.
Eligibility criteria and follow‑up
All the patients included in the OPERAM trial who were 
alive, had not withdrawn and were not lost to follow-up 
at hospital discharge, and had full medication data dur-
ing the index hospitalization were included in this sub-
study (to be able to measure our main criterion) [19]. 
Patients with medication data at time t, but with no med-
ication data at  t− 1, were censored at  t− 1. For example, a 
few patients had medication data at 6 months but not at 
2 months; these patients were censored at 2 months.
Drug‑drug interactions: prevalence and characteristics
DDIs were identified using recently defined the list of 66 
potentially clinically significant DDIs [11]. Throughout 
the rest of the manuscript, the term “DDI” is used to refer 
to these potentially clinically significant DDIs.
The drugs most frequently involved in DDIs are car-
diovascular, antithrombotic and central nervous sys-
tem drugs. The expert panel list provides details on the 
type and mechanism of the DDI (i.e., pharmacodynamic, 
pharmacokinetic or both), potential harmful effect(s), 
and management (Additional file 1). An algorithm based 
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on the Anatomical Therapeutic Chemical (ATC) codes of 
the 66 DDIs was developed (available via https://github.
com/agapiospanos/DDI). This algorithm was used to 
identify DDIs in our patients at the different time points.
In the present study, potential harm resulting from 
the DDI was evaluated by allocating each DDI to one of 
the following categories: serious cardiovascular adverse 
effects; serious neurological adverse effects; bleeding; 
deterioration of renal function and/or hyperkalemia 
(including severe myopathy and rhabdomyolysis, which 
may lead to acute renal failure); hematologic toxicity; and 
miscellaneous others (Additional file 2).
Changes in prevalence of DDIs
The prevalence of DDIs at 2 months post-randomiza-
tion compared to that at baseline was defined as having 
increased if there was a new prescription giving rise to 
one or more new DDIs or decreased if deprescription had 
resulted in removal of one or more DDIs. The 2-month 
time point was chosen to assess the effect of treatment 
changes considered during hospitalization, including the 
weeks following hospital discharge when prescriptions 
may be adjusted by the general practitioner, for example. 
This was also the time point selected for several second-
ary outcomes of the original OPERAM study and there-
fore all the data were available at this time point [19, 20].
Statistical analysis
The point-prevalence of DDIs at the different time points 
(baseline, discharge, 2, 6 and 12 months post-randomi-
zation) was evaluated in total (at least one DDI) and for 
each DDI separately, and then according to the type of 
interaction (i.e., pharmacokinetic, pharmacodynamic), 
the potential harm, the randomization arm, and the trial 
site. The most common DDIs in this population were 
defined using the 3rd quartile of the most frequent DDIs. 
McNemar’s test was used to assess differences in preva-
lence between baseline and discharge. The chi-squared 
test for trend was used to assess the trend in prevalence 
between discharge and 1 year after trial enrollment.
Data are presented as median (25–75% interquartile 
range [IQR]) for continuous variables, and numbers (per-
centages) for categorical variables. A Mann-Whitney U 
test or Kruskall-Wallis test was used to compare continu-
ous variables between groups and Pearson’s chi-squared 
test or Fisher’s exact test to compare categorical variables 
between groups.
Binary logistic regression models were performed to 
assess independent variables, present at baseline (age, 
sex, trial site, medical history, medications, functional 
autonomy, type of admission, main reason for hospital 
admission), associated with (i) the presence of at least 
one DDI at inclusion, and (ii) a change in prevalence of 
at least one DDI at 2 months (increase or decrease com-
pared to baseline). All variables with a P < .15 on univari-
ate analysis were included in the multivariable model. 
Correlations were assessed between quantitative vari-
ables (Pearson coefficient) and qualitative variables (Phi 
coefficient). The choice between two correlated variables 
was based on their respective clinical relevance. Missing 
data were not imputed.
All tests were 2-sided, and a P < .05 was considered sta-




A total of 2008 patients were enrolled in the OPERAM 
trial, of whom 1950 were alive and had medication data 
available at discharge and were included in this substudy 
(Fig. 1). The median age [IQR] was 79 [74–84] years; 1080 
patients (55%) were male; the median [IQR] number of 
drugs per day was 12 [9–16]. Baseline characteristics are 
given in Table 1 (Additional file 3). [Place of Table 1] The 
median length of stay [IQR] was 7 [3–10] days.
At baseline, 1045 (54%) patients had at least one DDI 
(Table  1) [median number of DDIs per person [IQR] 
with at least one DDI: 1[1–2]). Certain medical condi-
tions (depression, coronary artery disease, heart failure, 
atrial fibrillation, chronic obstructive pulmonary dis-
ease [COPD]) and polypharmacy were risk factors for 
the presence of at least one DDI at baseline, with ORs 
varying between 1.25 [1.02–1.54] and 2.88 [1.99–4.26] 
(Table  2). Age over 80 years (80–89 years: 0.79 [0.64–
0.97], ≥90 years: 0.65 [0.44–0.96]) and a history of 
chronic hepatic failure (0.49 [0.31–0.77]) were associated 
with a lower prevalence of DDIs (Table 2).
Point‑prevalence of DDIs over time
The point-prevalence rates for at least one DDI were 54, 
58, 57, 56 and 57% at baseline, hospital discharge and 
at 2, 6 and 12 months from the index hospitalization, 
respectively (Fig. 2A, Additional file 4). The prevalence of 
DDIs increased significantly during the index hospitaliza-
tion (McNemar test, P < .001), then remained stable over 
time (Chi-squared test for trend, P = .31). The observed 
increase from baseline to discharge was notable for phar-
macodynamic DDIs (but not for pharmacokinetic DDIs) 
(Fig. 2B), and for DDIs potentially associated with cardio-
vascular adverse events (Fig. 2C).
The five most prevalent DDIs in our cohort were: DDI 
65 (prescription of ≥2 drugs that reduce potassium), 
DDI 36 (prescription of ≥3 centrally-acting drugs), 
DDI 21 (prescription of ≥2 potassium-sparing drugs), 
DDI 12 (oral anticoagulant and antiplatelet) and DDI 39 
(oral non-steroidal anti-inflammatory drug and selective 
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serotonin reuptake inhibitor or serotonin-norepineph-
rine reuptake inhibitor) (Fig. 2A, Additional file 4). These 
five DDIs accounted for 78% of all DDIs at baseline, 80% 
at discharge and 83% thereafter. They were all classified 
as pharmacodynamic interactions (Additional file 1).
The main drug classes involved in the three most fre-
quent DDIs are listed in Additional file 5 (DDI 65: high 
ceiling diuretics, inhaled beta2 agonists, systemic cor-
ticosteroids and contact laxatives; DDI 36: antipsy-
chotics, anxiolytics, hypnotics and sedatives, opioids, 
antidepressants and antiepileptics; DDI 21: agents acting 
on the renin-angiotensin system and spironolactone).
As described in Fig.  2D and Additional  files  6–7, the 
prevalence of DDIs during the index hospitalization only 
increased in patients randomized to the control arm, as 
compared to the intervention arm, and hospitalized in 
Bern, as compared to other sites. Patients’ baseline char-
acteristics and types of admission were different across 
the sites (Additional file 8). Patients in Bern, compared to 
other sites, had more comorbidities, more polypharmacy, 
Fig. 1 Flow chart
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and were generally hospitalized for non-elective reasons 
(Additional file 8).
Changes in prevalence of DDIs at 2 months compared 
to baseline
At 2 months, DDIs had increased in 459 (27%) patients 
and decreased in 331 (19%) patients compared to at 
baseline (Additional  files  9 and 10). Female sex, hyper-
polypharmacy (≥10 drugs per day at baseline), history of 
depression and heart failure were significantly associated 
with a decrease in DDIs at 2 months (Table 3). History of 
atrial fibrillation, coronary heart disease, or cardiac fail-
ure and hyperpolypharmacy were significantly associated 
with an increase in DDIs at 2 months (Table 3).
Discussion
Key findings
In a European cohort of older patients with multimor-
bidity and polypharmacy, the prevalence of potentially 
clinically significant DDIs was high (54%) at hospital 
admission. Patients with certain medical conditions, such 
as depression, coronary artery disease, heart failure, atrial 
fibrillation and COPD, and those with polypharmacy 
were more likely to have at least one DDI at baseline. The 
top five most frequent potentially clinically significant 
DDIs (drugs that reduce potassium [diuretics, inhaled 
beta2 agonists, systemic corticosteroids], centrally-
acting drugs [psychotropics, antidepressants, opioids, 
antiepileptics], potassium-sparing drugs [angiotensin-
converting enzyme, angiotensin II type 1 receptor block-
ers, spironolactone] and antithrombotics] comprised 
80% of all potentially clinically significant DDIs. These 
five potentially clinically significant DDIs were all clas-
sified as pharmacodynamic interactions mainly causing 
cardiovascular adverse events. The prevalence of poten-
tially clinically significant DDIs increased significantly at 
discharge and then remained stable over the subsequent 
12 months (i.e., did not return to the baseline prevalence 
level).
Comparisons with previous studies
The high prevalence of DDIs in our cohort aligns with the 
in-patient and out-patient prevalences reported in the lit-
erature for comparable populations (geriatric outpatient 
cohort: 44.5% [24] and 58.3% [25]; geriatric inpatient 
cohort: 60.5% [26]). The drug classes most frequently 
involved in DDIs in our cohort were also the same as 
those previously reported [1, 4, 16, 17, 26–29]. These 
drugs are often prescribed to older patients to treat com-
mon age-related conditions, particularly cardiovascular 
and neurological conditions. Consistent with our results, 
Vonbach et al. reported that more than 70% of all major 
and moderately severe potential DDIs were pharmacody-
namic interactions [30].
In line with our results, two studies reported that hos-
pitalization was associated with an increase in DDIs in 
older patients, [26, 30] one of which reported that almost 
half of the DDIs at hospital discharge were incurred dur-
ing hospitalization [30]. However, and this is the original-
ity of our study, none of the published studies assessed 
DDIs over time to describe trends after discharge in older 
patients. Changes in the prevalence of DDIs over time, 
with a higher prevalence at discharge than at baseline, 
and a decrease after hospital discharge but not to baseline 
levels, were noted particularly for DDI 65 (concomitant 
prescription of ≥2 drugs that reduce potassium), which 
includes cardiovascular and respiratory drugs (high ceil-
ing diuretics and inhaled beta2 agonists). This trend has 
already been described in patients with coronary heart 
disease and COPD, [31] conditions for which these drugs 
are indicated. In addition, factors associated with an 
increase in DDIs at 2 months were similar to those pre-
viously reported in the literature, especially polyphar-
macy [2–4, 7, 32]. The fact that the patients included in 
Bern had more comorbidities, were more likely to have 
Table 2 Multivariable analysis of risk factors for the presence of 
drug-drug interactions at baseline (index hospitalization)
N = 1950; AIC = 2490
C statistic: 0.69 IC95% (0.68–0.72).
a  Baseline = Index hospitalization
b  ≥ 10 drugs par day at admission.
c  Non-independent living was defined as living in a nursing home (at least 
3 months in the 6 months before the index admission) or being housebound.
d Classification coded from the main reasons for hospitalization (free text in the 
original database)
Abbreviations: AIC Akaike’s criterion, COPD chronic obstructive pulmonary 
disease
Variables at  baselinea OR (95% CI) P value
Age (reference: 70–79 years)
    - 80–89 years






    - male
0.81 [0.66–0.98] .03
Medical history of depression 2.88 [1.99–4.26] < .001
Medical history of coronary artery disease 1.25 [1.02–1.54] .03
Medical history of heart failure 1.60 [1.26–2.02] < .001
Medical history of atrial fibrillation 1.55 [1.26–1.90] < .001
Medical history of chronic renal failure 1.09 [0.87–1.36] .46
Medical history of chronic hepatic failure 0.49 [0.31–0.77] .002
Medical history of COPD 1.91 [1.48–2.47] < .001
Hospitalizations during the previous year 1.17 [0.96–1.42] .10
Hyperpolypharmacy 2.21 [1.77–2.77] < .001
Non‑independent livingc 1.26 [0.98–1.63] .06
Main reason for hospital admission (refer‑
ence: surgical)d
    - Medical
1.09 [0.82–1.45] .55
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polypharmacy, and were generally hospitalised for non-
elective reasons, may explain the differences in trends 
across trial sites.
DDIs are often classified according to their potentially 
harmful effects, but no study has reported the preva-
lence of DDIs according to whether or not they may be 
appropriate. Evaluation of appropriateness of a DDI often 
requires an individual, case-by-case assessment, which 
is not possible on a large database. However, from the 
list of 66 DDIs, some can be considered inappropriate 
in many cases (“avoid concurrent use”), such as DDI 32, 
“beta-blocker and verapamil or diltiazem” (potentially 
Fig. 2 Point-prevalence rates of drug-drug interactions (DDIs) over time. A: prevalence in all patients with at least one DDI and for the most 
frequent DDIs; B: prevalence according to pharmacokinetic and pharmacodynamic status; C: prevalence according to potential harm; D: prevalence 
according to the OPERAM trial randomization arm. McNemar’s test was used to assess differences in prevalence between baseline and discharge. 
Chi-squared test for trend was used to assess the prevalence trend between discharge and 1 year after the inclusion. Only p values ≤0.05 are 
specified, other p values are > 0.5 All DDIs, the types of interaction for each DDI, and details on their potential harm are described in Additional 
file 1. DDI 11: oral anticoagulant + an oral non-steroidal anti-inflammatory drug. DDI 12: oral anticoagulant + an antiplatelet drug. DDI 21: 
concomitant use of ≥2 potassium-sparing drugs. DDI 23: angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blockers + an 
oral non-steroidal anti-inflammatory drug. DDI 27: simvastatin + amlodipine. DDI 28: atorvastatin or simvastatin or lovastatin + amiodarone. DDI 30: 
calcium channel blocker + a CYP3A4 inhibitor (cytochrome P450). DDI 36: concomitant use of ≥3 centrally-acting drugs. DDI 38: selective serotonin 
reuptake inhibitor + another serotonergic drug. DDI 39: oral non-steroidal anti-inflammatory drug + selective serotonin reuptake inhibitor or 
serotonin-norepinephrine reuptake inhibitor. DDI 56: oral or parenteral corticosteroid + an oral non-steroidal anti-inflammatory drug. DDI 6: digoxin 
+ thiazide or loop diuretic. DDI 65: concomitant prescription of ≥2 drugs that reduce potassium. DDI 66: selective serotonin reuptake inhibitor + 
loop or thiazide diuretic. Abbreviations: M: month, PD: pharmacodynamic, PK: pharmacokinetic, M: month
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serious cardiovascular adverse effects in particular in 
patients predisposed to heart failure); DDI 36, “concomi-
tant use of ≥3 centrally-acting drugs” (increased risk of 
falls, fracture, impaired cognition); and DDI 63, “tamox-
ifen and paroxetine or fluoxetine or bupropion” (risk 
of sudden death – ventricular arrhythmias, torsade de 
pointes). Most drugs in these DDI categories were rarely 
prescribed in our cohort with the exception of DDI 36. 
Other DDIs may be appropriate, or even intentional, in 
some cases if preventive measures are taken (e.g., dose 
adaptation, close monitoring, patient education), for 
example, for DDI 12, “oral anticoagulant and antiplatelet 
drug”; DDI 65, “concomitant prescription of ≥ 2 drugs 
that reduce potassium”; and DDI 66: “selective seroto-
nin reuptake inhibitor and loop or thiazide diuretic”. DDI 
65 prescribed in acute clinical situations, such as car-
diac failure or COPD exacerbation, may, for example, be 
appropriate if serum potassium concentrations are moni-
tored closely. Similarly, DDI 12 is only appropriate in cer-
tain specific clinical situations (e.g., atrial fibrillation and 
recent acute coronary syndrome) and for a fixed duration 
[33]. The fact that 57% of patients in the experimental 
arm (i.e., patients for whom medication review was per-
formed by a physician and pharmacist) had at least one 
DDI at hospital discharge suggests that most of these 
DDIs were considered appropriate in these patients and 
thus did not require drug discontinuation or modifica-
tion after the medication review. Only the patients in the 
control arm had an increase in the prevalence of DDI 36 
from baseline to discharge, which may explain why there 
was a significant increase in the prevalence of DDIs dur-
ing hospitalization only in patients in the control arm. 
These data suggest that frequent medication reviews 
for those admitted to hospital, not only during hospital 
admission, but also after discharge, can contribute to 
reducing the risk of inappropriate DDIs.
Strength and limitations
To our knowledge, this is the first international, multi-
center study to report data on the prevalence of DDIs 
at hospital admission and at different time points over 
a one-year follow-up period in an older population 
with multimorbidity. To identify the DDIs, we used for 
the first time a new list of 66 potentially clinically sig-
nificant DDIs developed by an international consensus 
panel [11].
This study has some limitations. First, we were unable 
to distinguish between appropriate and inappropriate 
DDIs (which would require detailed information on, 
for example, dose adaptations, indications, monitoring, 
patient specifics). Second, because of a lack of statis-
tical power, we did not assess ADEs and drug-related 
hospital admissions associated with DDIs. This infor-
mation would have enabled us to evaluate actual DDIs 
resulting from potential DDIs. As reported in the lit-
erature, it is therefore likely that we have overestimated 
the true clinical significance of the DDIs [3]. Indeed, 
studies that focused on actual DDIs reported lower 
prevalences in ambulatory settings (9.5 and 25.5%) [24, 
34] as well as for in-patients (8.8%) [35]. Neverthe-
less, the presence of a potentially clinically significant 
DDI remains a strong signal that should alert the pre-
scriber to the need for greater patient monitoring and 
education.
Table 3 Multivariable analysis of factors predictive of change 
in prevalence (increase or decrease) of drug-drug interactions 
(DDIs) at 2 months compared to baseline
Deprescription: N = 1722, AIC = 1647.9, C statistics: 0.63 IC95% (0.61–0.67).
Prescription: N = 1701, AIC = 1857, C statistics: 0.69 IC95% (0.67–0.73).
a  Baseline = Index hospitalization
b  ≥ 10 drugs par day at admission
Univariate analyses are described in Additional files 9 and 10
Abbreviations: AIC Akaike’s criterion, ADL activities of daily living, COPD chronic 
obstructive pulmonary disease
Variables at  baselinea OR (95% CI) P value
Decrease in DDI
Sex (reference: female)
Male 0.76 [0.59–0.98] .03
Site (reference: Bern)
    - Louvain 1.24 [0.87–1.74] .22
    - 1Utrecht 1.12 [0.80–1.55] .51
    - Cork 0.70 [0.47–1.02] .06
Medical history of depression 1.69 [1.14–2.48] .008
Medical history of atrial fibrillation 1.29 [0.99–1.67] .05
Medical history of coronary heart disease 1.17 [0.90–1.53] .23
Medical history of heart failure 1.37 [1.04–1.81] .03
Medical history of COPD 1.21 [0.88–1.63] .23
Medical history of cancer 0.80 [0.58–1.07] .14
Hyperpolypharmacyb 2.02 [1.44–2.88] < .001
Increase in DDI
Site (reference: Bern)
    - Louvain 0.72 [0.50–1.02] .07
    - Utrecht 0.69 [0.50–0.95] .02
    - Cork 0.53 [0.37–0.74] < .001
Medical history of dementia 1.18 [0.75–1.85] .46
Medical history of depression 1.30 [0.88–1.90] .17
Medical history of atrial fibrillation 2.01 [1.59–2.55] < .001
Medical history of coronary heart disease 1.29 [1.01–1.64] .04
Medical history of cardiac failure 1.79 [1.39–2.30] < .001
Medical history of chronic renal failure 0.85 [0.65–1.10] .23
Medical history of bleeding 1.29 [0.93–1.77] .11
Hyperpolypharmacyb 1.74 [1.29–2.37] < .001
ADL 0.95 [0.87–1.03] .19
Main reason for hospital admission (reference: surgical)
    - Medical 1.32 [0.90–1.97] .16
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Table 1 Demographic data and baseline characteristics of patients included in the cohort, stratified by drug-drug interaction (DDI) 
status at baseline
a  Baseline = Index hospitalization
b  ≥ 10 drugs par day at admission
c  Non-independent living was defined as living in a nursing home (at least 3 months in the 6 months before the index admission) or being housebound
d  Elective procedure for a pre-existing condition
Data are median [P25; P75] or n (%). Comparison between the two groups using Mann-Whitney U test for quantitative variables and chi-square test or Fisher’s exact 
test for qualitative variables
Abbreviations: COPD chronic obstructive pulmonary disease
Total
N = 1950
At least one DDI at 
 baselinea
N = 1045
No DDI at  baselinea
N = 905
Missing values P value
Age (years)
Median (IQR) 79 [74–84] 78 [74–83] 79 [74–85] 0 .13
.2570–79 1053 (54) 582 (56) 471 (52)
80–89 757 (39) 393 (37) 364 (40)
>  90 140 (7) 70 (7) 70 (8)
Male 1080 (55) 558 (53) 522 (58) 0 .06
Trial site
Louvain, Belgium 385 (20) 206 (20) 179 (20) 0 .25
Cork, Ireland 328 (17) 171 (16) 157 (17)
Utrecht, The Netherlands 433 (22) 250 (24) 183 (20)
Bern, Switzerland 804 (41) 418 (40) 386 (43)
Medical history
Dementia 116 (6) 65 (6) 51 (6) 0 .65
Depression 173 (9) 132 (13) 41 (5) < .001
Stroke 410 (21) 207 (20) 203 (22) .17
Hypertension 1282 (66) 675 (65) 607 (67) .27
Atrial fibrillation 697 (36) 436 (42) 261 (29) < .001
Diabetes 628 (32) 346 (33) 282 (31) .38
Coronary artery disease 661 (34) 385 (37) 276 (31) .004
Heart failure 500 (26) 333 (32) 167 (19) < .001
Chronic renal failure 522 (27) 302 (29) 220 (24) .03
Chronic hepatic failure 98 (5) 41 (4) 57 (6) .02
COPD 375 (19) 258 (25) 117 (13) < .001
Cancer 482 (25) 249 (24) 233 (26) .35
Bleeding 250 (13) 137 (13) 113 (12) .73
Thromboembolic disease 236 (12) 133 (13) 103 (11) .40
Number of comorbidities 11 [8–16] 11 [8–16] 11 [8–15] .002
Medications on index admission
Number of drugs per day 12 [9–16] 14 [11–18] 11 [8–14] 0 < .001
Hyperpolypharmacyb 1458 (75) 873 (83) 585 (65)
Any hospitalizations during the previous year










Not living independentlyc 375 (19) 222 (21) 153 (17) 0 .02
ADL6 score 5.5 [4.5–6.0] 5.5 [4.5–6.0] 5.5 [4.5–6.0] 32 .61
Education level
Less than high school education 573 (30) 326 (32) 247 (28) 24 .16
High-school degree 886 (46) 463 (45) 423 (47)
Post-secondary degree 467 (24) 243 (23) 224 (25)
Type of admission
Electived 473 (24) 243 (23) 230 (25) 0 .29
Non-elective 1477 (76) 802 (77) 675 (75)
Main reason for hospital admission
Surgical 257 (13) 120 (11) 137 (15) 0 .02
Medical 1693 (87) 925 (89) 768 (85)
Page 9 of 11Zerah et al. BMC Geriatr          (2021) 21:571  
Perspectives
It seems important to help clinicians identify potentially 
harmful DDIs more effectively, in particular the five most 
prevalent, to improve their assessment of risk-benefit 
ratios in individual patients. Risk minimization measures 
for prescription of psychotropic drugs, antithrombotics 
and drugs that reduce or increase potassium concentra-
tions should be deployed.
The next logical step would be to assess the clini-
cal impact of these DDIs, especially of the most com-
mon ones. To this end, a large scale cohort study from 
healthcare databases could be carried out. Better identi-
fication of the impact of DDIs is important for clinicians, 
researchers and health policy decision-makers to plan for 
safer healthcare in ageing societies.
Conclusions
In a European cohort of older patients with multimorbid-
ity and polypharmacy, we evaluated, for the first time, the 
prevalence of DDIs over a 12-month interval using a new 
list of 66 potentially clinically significant DDIs in older 
patients. The prevalence of DDIs in hospital and after dis-
charge was high, with more than half the cohort having 
at least one DDI within their medication regimen. Pre-
scriptions resulting in additional DDIs occurred during 
the index hospital stay (in particular in the control group 
without medication review) and tended to remain stable 
thereafter. Many of these DDIs were probably appropri-
ate/deliberate at a patient level, if adequate management 
measures (mainly monitoring and patient education) are 
taken. Efforts should be directed at identifying inappro-
priate/potentially dangerous DDIs. Medication review 
during the hospital stay should help achieve this.
Further evaluation of the performance of the DDI list 
in terms of its association with clinical outcomes and 
identification of associated factors will be useful to fur-
ther refine the list and identify inappropriate DDIs and 
avoidable ADEs.
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